Current Hypertension Reports

, Volume 1, Issue 6, pp 521–528 | Cite as

Hypertensive cardiovascular disease in African Americans

  • Ravinder K. Wali
  • Matthew R. Weir


Hypertension is the most common public health challenge in the United States because of its prevalence and associated increase in comorbid cardiovascular diseases [1]. Yearly expenses related directly or indirectly to the treatment and detection of hypertension in the United States are approximately $10 billion, excluding the enormous yearly financial burden of $259 billion and the social burden from heart disease and stroke, which remain the first and third leading causes of death, respectively, in the United States [2]. Despite the importance of these observations, blood pressure is poorly controlled in the United States.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Dustan HP, Roccella EJ, Garrison HH: Controlling hypertension: a research success story. Arch Intern Med 1996, 156:1926–1935.PubMedCrossRefGoogle Scholar
  2. 2.
    National Institutes of Health, National Heart, Lung, and Blood Institute: Morbidity and mortality 1996: chartbook on cardiovascular, lung, and blood diseases: data points document. Bethesda: National Institutes of Health; 1996.Google Scholar
  3. 3.
    The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 157:2413–2446. Using evidence-based medicine and consensus this report describes the national guidelines for hypertension control with a special emphasis on risk stratification in patients with hypertension. It also provides evidence for the use of combination of antihypertensive medications for hypertension control in the high risk groups.Google Scholar
  4. 4.
    Kaplan NM: Ethnic aspects of hypertension. Lancet 1994, 344:45–52.Google Scholar
  5. 5.
    Cooper R, Rotimi C: Hypertension in populations of West African origins: is there a genetic predisposition? J Hypertens 1994, 12:215–227.PubMedCrossRefGoogle Scholar
  6. 6.
    Burt VL, Whelton P, Roccella EJ, et al.: Prevalence of hypertension on the adult US population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995, 25:305–313.PubMedGoogle Scholar
  7. 7.
    Berlowitz DR, Ash AS, Hickey EC, et al.: Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998, 339:1957–1963. This is on of the few studies in hypertension in which process of care for single visit was examined in detail. The study demonstrates that physician’s awareness is an important determinant of optimal bloo pressure control.PubMedCrossRefGoogle Scholar
  8. 8.
    O’Donnell CJ, Kannel WB: Is there a racial predisposition to hypertension? Hypertension 1998, 32:817–819. This is a comprehensive editorial about polygenic etiology of hypertension in African Americans.PubMedGoogle Scholar
  9. 9.
    Weinberger MH: More spice on the salt debate. Arch Intern Med 1997, 157:2407–2408.PubMedCrossRefGoogle Scholar
  10. 10.
    Weinberger MH: Salt sensitivity of blood pressure in humans. Hypertension 1996, 27:481–490.PubMedGoogle Scholar
  11. 11.
    Intersalt Cooperative Research Group: Intersalt: and international study of electrolyte excretion and blood pressure. BMJ 1988, 297:319–328.CrossRefGoogle Scholar
  12. 12.
    Midgley JP, Matthew AG, Greenwood CMT, Logan AG: Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA 1996, 275:1590–1597.PubMedCrossRefGoogle Scholar
  13. 13.
    Cutler JA, Foreman D, Elliocott P, Suh I: An overview of randomized trials of sodium reduction and blood pressure. Hypertension 1996, 17(suppl 1):127–133.Google Scholar
  14. 14.
    Weir MR, Dengel DR, Behrens MT, Goldberg AP: Salt-induces increase in systolic blood pressure affect renal hemodynamics and proteinuria. Hypertension 1995, 25:1339–1344.PubMedGoogle Scholar
  15. 15.
    Campese VM, Parise M, Karubian F, et al.: Abnormal renal hemodynamcis in black salt-sensitive patients with hypertension. Hypertension 1991, 18:805–812.PubMedGoogle Scholar
  16. 16.
    Cooper R, Aina O, Chaco L: Cell cation and blood pressure in US whites, US blacks, and West African blacks. J Hum Hypertens 1990, 4:477–484.PubMedGoogle Scholar
  17. 17.
    Chrysant SG, Danisa K, Kem DC, et al.: Racial differences in pressure, volume and renin interrelationships in essential hypertension. Hypertension 1979, 1:136–141.PubMedGoogle Scholar
  18. 18.
    Zinner SH, Margolius HS, Rosner B, et al.: Familial aggregation of urinary kallikrein concentration in childhood: relation of blood pressure, race and urinary electrolytes. Am J Epidemiol 1976, 104:124–132.PubMedGoogle Scholar
  19. 19.
    Levy SB, Lilley JJ, Frigon RP, et al.: Urinary kallikrein and plasma renin activity as determinants of renal blood flow: the influence of race and dietary sodium intake. J Clin Invest 1977, 60:129–138.PubMedCrossRefGoogle Scholar
  20. 20.
    Anderson NB, Lane JD, Monou H, et al.: Racial differences in cardiovascular reactivity to mental arithmetic. Int J Psychophysiol 1988, 6:161–164.PubMedCrossRefGoogle Scholar
  21. 21.
    Frohlich ED, Messerli FH, Dunn FG, et al.: Greater renal vascular involvement in the black patient with essential hypertension: a comparison of systematic and renal hemodynamic in blacks and white patients. Miner Electrolyte Metab 1996, 1984:173–177.Google Scholar
  22. 22.
    Weir MR, Tuck ML: Essential hypertension in blacks: it is a metabolic disorder ? Am J Kidney Dis 1993, 21:58–67.PubMedGoogle Scholar
  23. 23.
    He J, Klag MJ, Caballero B, et al.: Plasma insulin level and incidence of hypertension in African-Americans and whites. Arch Intern Med 1999, 159:498–503. A prospective study of 377 subjects (140 African Americans and 237 whites) from the cohort of 463 subjects initially enrolled for TOHP-I and followed for 7.1 years. This study demonstrates the effect of baseline insulin levels and insulin-to-glucose ratio on blood pressure in African Americans.PubMedCrossRefGoogle Scholar
  24. 24.
    Kaufman JS, Durazo-Avizu RA, Rotimi CN, et al.: Obesity and hypertension prevalence in populations of African origin: results from the International Collaborative Study on Hypertension in Blacks. Epidemiology 1996, 7:398–405.PubMedCrossRefGoogle Scholar
  25. 25.
    Beaglehole T, Tyroler HA, Cassel JC, et al.: An epidemiological study of left ventricular hypertrophy in the biracial population of Evans County, Georgia. J Chron Dis 1975, 28:549–559.PubMedCrossRefGoogle Scholar
  26. 26.
    Taylor JO, Borhani NO, Entwisle G, et al.: Hypertension Detection and Follow-up Program Cooperative Group: summary of the baseline characteristics of the hypertensive participants. Hypertension 1983, 5:44–50.Google Scholar
  27. 27.
    Savage DD, Henry WL, Mitchell JR, et al.: Echocardiographic comparison of black and white hypertensive subjects J Natl Med Assoc 1979, 71:709–712.PubMedGoogle Scholar
  28. 28.
    Levy D, Anderson KM, Savage DD, et al.: Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Study. Ann Intern Med 1988, 108:7–13.PubMedGoogle Scholar
  29. 29.
    Gardin JM, Wagenknecht LE, Anton-Culver H, et al. Relationship of cardiovascular risk factors to echocardiographic left ventricular mass in healthy young black and white adult men and women. The CARDIA study. Circulation 1995, 92:380–387.PubMedGoogle Scholar
  30. 30.
    Arnett DK, Rautaharju P, Crow R, et al.: Black-white differences in electrocardiographic left ventricular mass and its association with blood pressure (the ARIC Study). Am J Cardiol 1994, 74:247–252.PubMedCrossRefGoogle Scholar
  31. 31.
    Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561–1566.PubMedCrossRefGoogle Scholar
  32. 32.
    Liao Y, Cooper RS, McGee DL, et al.: The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995, 273:1592–1597.PubMedCrossRefGoogle Scholar
  33. 33.
    Liao Y, Cooper RS, Durazo-Arvizu R, et al.: Prediction of mortality risk by different methods of indexation for left ventricular mass. J Am Coll Cardiol 1997, 29:641.PubMedCrossRefGoogle Scholar
  34. 34.
    Pringle SD, Dunn FG, Macfarlan PW, et al.: Significance of ventricular arrhythmias in systematic hypertensive patients with left ventricular hypertrophy. Am J Cardiol 1992, 69:913–917.PubMedCrossRefGoogle Scholar
  35. 35.
    The Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program: prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy. Hypertension 1985, 7:105–112.Google Scholar
  36. 36.
    Frohlich ED, Epstein C, Chbanian AV, et al.: The heart in hypertension. N Engl J Med 1992, 74:247–252.Google Scholar
  37. 37.
    Mosterd A, D’Agostino RB, Silbershatz H, et al.: Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999, 340:1221–1227. [Editorial comment on page 1279–1280.] The authors describe the follow-up of 50 years in the Framingham Heart Study Cohort with longitudinal electrocardiographic data, and importance of blood pressure reduction and regression of left ventricular hypertrophy regardless of the type of antihypertensive medication used to control the blood pressure.PubMedCrossRefGoogle Scholar
  38. 38.
    Caplan LR: Strokes in African-Americans. Circulation 1991, 83:1469–1471.PubMedGoogle Scholar
  39. 39.
    Fisher CM: Clinical syndromes in cerebral thrombosis, hypertensive hemorrhage and ruptured saccular aneurysm. Clin Neurosurg 1975, 22:117–129.PubMedGoogle Scholar
  40. 40.
    Rosamond WD, Folsom AR, Chambless LE, et al.: Stroke incidence and survival among middle-aged adults: 9-year follow-up of the atherosclerosis risk in communities (ARIC) cohort. Stroke 1999, 30:736–743. This is a 7.2 years follow-up study of 15792 in four US communities and revealed nearly 40% higher incidence of ischemic strokes in African Americans compared with whites.PubMedGoogle Scholar
  41. 41.
    Zampaglione B, Pascale C, Marchismo M, Cavallo-Perin P: Hypertensive urgencies and emergencies: prevalence and clinical presentation. Hypertension 1996, 27:114–147.Google Scholar
  42. 42.
    The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Renal Data Systems 1991 Annual Report. Bethesda: 1991, 13–20: A1–A22.Google Scholar
  43. 43.
    Powers RD, Wallin JD: End-stage renal disease in specific ethnic and racial groups: risk factors and benefits of antihypertensive therapy. Arch Intern Med 1998, 158:793–800. This is a in depth review of various risk factors in African American and Native Americans, two high risk groups for the development of hypertension and hypertension related renal failure and risk of progression to end-stage renal disease.PubMedCrossRefGoogle Scholar
  44. 44.
    Feldman HI, Klag MJ, Chiapella AP, Whelton PK: End-stage renal disease in US minority groups. Am J Kidney Dis 1992, 19:397–410.PubMedGoogle Scholar
  45. 45.
    Walker WG, Neaton JD, Cutler JA, et al.: Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: racial and treatment effects. JAMA 1992, 268:3085–3091.PubMedCrossRefGoogle Scholar
  46. 46.
    Shulman ND, Ford CE, Hall WD, et al.: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the Hypertension Detection and Follow-up Program. Hypertension 1989, 13:180–193.Google Scholar
  47. 47.
    Rostand SG, Brown G, Kirk KA, et al.: Renal insufficiency in treated essential hypertension. N Engl J Med 1989, 320:684–688.PubMedCrossRefGoogle Scholar
  48. 48.
    Frohlich ED, Messerli FH, Dunn FG, et al.: Greater renal vascular involvement in the black patient with essential hypertension: a comparison of systemic and renal hemodynamics in black and white patients Miner Electrolyte Metab 1984, 10:173–177.PubMedGoogle Scholar
  49. 49.
    Levy SB, Talner LB, Coel MR, et al.: Renal vasculature in essential hypertension: Racial differences. Ann Intern Med 1978, 88:12–16.PubMedGoogle Scholar
  50. 50.
    Pitcock JA, Johnson JG, Hatch FE, et al.: Malignant hypertension in blacks. Malignant intrarenal arterial disease as observed by light and electron microscopy. Hum Pathol 1976, 7:333–346.PubMedCrossRefGoogle Scholar
  51. 51.
    Brazy PC, Stead WW, Fitzwilliam JF: Progression of renal insufficiency: role of blood pressure. Kidney Int 1989, 35:670–674.PubMedCrossRefGoogle Scholar
  52. 52.
    Perneger TV, Whelton PK, Klag MJ, et al.: Diagnosis of hypertensives end-stage renal disease: effect of patient’s race. Am J Epidemiol 1995, 141:10–15.PubMedGoogle Scholar
  53. 53.
    Wright JT Jr, Kirk KA, Kusek JW, et al.: Design of the African-American study of Kidney Disease and Hypertension (AASK) pilot study. Control Clin Trials 1996, 17:3S-16S.PubMedCrossRefGoogle Scholar
  54. 54.
    Sowers JR, Epstein M: Diabetes mellitus and associated hypertension vascular disease, and nephropathy: an update. Hypertension 1997, 26:869–874.Google Scholar
  55. 55.
    National High Blood Pressure Education Program Working Group: National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994, 43:145–151.Google Scholar
  56. 56.
    Hypertension in Diabetes Study Group: HDS 2: increased risk of cardio-vascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993, 11:319–325.CrossRefGoogle Scholar
  57. 57.
    Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984, 310:356–361.PubMedCrossRefGoogle Scholar
  58. 58.
    Kaplan NM: The deadly quartet: upper body obesity, glucos intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989, 149:1514–1521.PubMedCrossRefGoogle Scholar
  59. 59.
    Krop JS, Coresh J, Chambless LE, et al.: A community-based study of explanatory factors for the excess risk for early renal function decline in blacks vs whites with diabetes: the atherosclerosis risk in communities studies. Arch Intern Med 1999, 159:1777–1783. This prospective study demonstrates that early and faster decline in diabetic African Americans is secondary to potentially modifiable factors with more than 80% reduction in excess risk after adjusting for the risk factors.PubMedCrossRefGoogle Scholar
  60. 60.
    Kasiske BL, Kalil RSN, Ma JZ, et al.: Effects of antihyertensive therapy on the kidney in patients with diabetes: a meta-regression analysis Ann Intern Med 1993, 118:129–138.PubMedGoogle Scholar
  61. 61.
    UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:705–713. UKPDS 38 is the muticenter, randomised, controlled study with 9 years follow-up of 1148 hypertensive patients with type 2 diabetes mellitus. This study demonstrates that effective control of blood pressure decreases proteinuria and slows the progression in renal failure.Google Scholar
  62. 62.
    Ooi WL, Budner NS, Cohen H, et al.: Impact of race on treatment response and cardiovascular disease among hypertensives. Hypertension 1989, 14:227–234.PubMedGoogle Scholar
  63. 63.
    Materson BJ, Reda DJ, Cushman WC, et al.: Single-rug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993, 328:914–921.PubMedCrossRefGoogle Scholar
  64. 64.
    Weir MR, Chrysant SG, McCarron DA, et al.: Influence of a race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or calcium channel antagonist in salt-sensitive hypertensives. Hypertension 1998, 31:1088–1096. This clinical study describes the influence of low- and high-salt diet on the antihypertensive effects of isradipine (calcium channel blocker) and enalapril (angiotensin converting enzyme blocker) in three ethnic groups (blacks, hispanics and whites) with hypertension.PubMedGoogle Scholar
  65. 65.
    Psaty BM, Smith NL, Siscovick DS, et al.: Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997, 227:739–745.CrossRefGoogle Scholar
  66. 66.
    Gottdiener JS, Reda DJ, Materson BJ, et al.: Importance of obesity, race and age to the cardiac structural and functional effects of hypertension: The Department of Veterans Affairs Cooperative Study Group on antihypertensive agents. J Am Coll Cardiol 1994, 24:1492–1498.PubMedCrossRefGoogle Scholar
  67. 67.
    Saunder E, Curry C, Hinds J, et al.: Labetolol compared to propranolol in the treatment of black hypertensive patients. J Clin Hypertens 1987, 3:294–302.Google Scholar
  68. 68.
    Luther RR, Klepper MJ, Maurath CJ, et al.: Efficacy of terazosin in the treatment of essential hypertension in blacks. J Hum Hypertens 1990, 4:151–153.PubMedGoogle Scholar
  69. 69.
    Williams GH: Converting enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988, 319:1517–1525.PubMedCrossRefGoogle Scholar
  70. 70.
    The SOLVD Investigator: Effect of enalapril on survival on patients with reduces left ventricular ejection fractions and chronic congestive heart failure. N Engl J Med 1991, 325:293–302.CrossRefGoogle Scholar
  71. 71.
    Weir MR, Gray JM, Paster R, et al.: Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 1995, 26:124–130.PubMedGoogle Scholar
  72. 72.
    Weir MR, Saunders E: Racial similarity in response to the angiotensin converting enzyme inhibitors trandolapril. Am J Hypertens 1996, 9:174–179.CrossRefGoogle Scholar
  73. 73.
    Israili ZH, Hall WD: Cough and angioneurotic edema associated with angiotensinogen — converting enzyme inhibitors therapy: a review of the literature and pathophysiology. Ann Intern Med 1992, 117:234–242.PubMedGoogle Scholar
  74. 74.
    Goodfriend TL, Elliott ME, Catt KJ: Angiotensin receptors and their antagonists. N Engl J Med 1996, 334:1649–1654.PubMedCrossRefGoogle Scholar
  75. 75.
    Hall WD, Reed JW, Flack JM, et al.: Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. Arch Intern Med 1998, 158:2029–2034. This is a randomized, double-blind study reporting equal efficacy and safety of three commonly prescribed calcium-channel blockers (amlodipine besylate, nifedipine coat core, and nifedipine gastrointestinal therapeutics (GITS) in the African-American population with hypertension.PubMedCrossRefGoogle Scholar
  76. 76.
    Weir R, Hall P, Behrens T, Flack JM. Salt and blood pressure responses to calcium antagonism in hypertensive patients. Hypertension 1997, 30[part 1]:422–427.PubMedGoogle Scholar
  77. 77.
    Appel LJ, Moore TJ, Obarzanek E, et al., for the DASH Collaborative Research Group: A clinical trial of the effects o dietary patterns on blood pressure. N Engl J Med 1997, 336:1117–1124.PubMedCrossRefGoogle Scholar
  78. 78.
    Trials of Hypertension Prevention Collaborative Research Group: Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high blood pressure: the Trials of Hypertension Prevention, phase II. Arch Intern Med 1997, 157:657–667.CrossRefGoogle Scholar
  79. 79.
    Puddey IB, Parker M, Beilen LJ, et al.: Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. Hypertension 1992, 20:533–541.PubMedGoogle Scholar
  80. 80.
    Kokkinos PF, Narayakn P, Collerman JA, et al.: Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. N Engl J Med 1995, 333:1462–1467.PubMedCrossRefGoogle Scholar
  81. 81.
    Agency for Health Care Policy and Research. You Can Quit Smoking: Consumer Guide. Washington, DC: US Dept of Health and Human Services; 1996. AHCPR publication 96-0695.Google Scholar

Copyright information

© Current Science Inc. 1999

Authors and Affiliations

  • Ravinder K. Wali
    • 1
  • Matthew R. Weir
    • 1
  1. 1.Division of Nephrology N3W143University of Maryland HospitalBaltimoreUSA

Personalised recommendations